drugset / Trial / NCT06649630

A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men

NCT06649630 ↗

Phase 1 Completed 95 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will test how different doses of study medicine (Inno8) work in the healthy men. The purpose of this study is to prove safety of Inno8 in healthy men, which will support further development of Inno8 in people with Haemophilia A. The study consists of three parts: single ascending dose (SAD), multiple ascending dose (MAD) and single subcutaneous dose (SSD). Each part will have more than one cohort (like sub-parts). No matter which part the participants will be enrolled in, they will either get the study medicine (Inno8) or a dummy medicine that looks like the study medicine but has no effect on the body (placebo). Which treatment participants get is decided by chance. The study medicine is a new medicine that cannot be prescribed by doctors. In the SAD and SSD part participants will receive a single injection of study medicine or placebo, and the study will last for up to 9 weeks. In the MAD part, participants will receive 1-2 tablets of study medicine or placebo daily for 10 days, and the study will last for up to 11 weeks.

Timeline

Start
2024-09-23
Primary completion
2026-03-26
Completion
2026-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0442-0344 A Unknown — Intravenous

Indications